The vaccine, mFLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season. The vaccine, mFLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season. In a clinical trial for people aged 50 to 64, the mRNA vaccine led to 27% fewer confirmed flu cases than the current standard vaccine. Health Secretary Robert F. Kennedy Jr. has been vocal about his disapproval of the mRNA vaccine platform. Last year, the Department of Health and Human Services canceled at least $500 million of federally funded mRNA vaccine development.